New Zealand approves cannabinoid Sativex for MS spasticity
This article was originally published in Scrip
Executive Summary
MedSafe, the New Zealand regulatory authority, has approved Sativex (nabiximols), the cannabinoid spray product from GW Pharmaceuticals, to treat spasticity due to multiple sclerosis (MS). A consent notice to distribute Sativex under Section 20 of the Medicines Act 1981 has been published in the New Zealand Gazette, the official newspaper of the Government of New Zealand.